Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan

Shian-Ying Sung1,2,3,4, Trang Thi Huynh Le5, Jin-Hua Chen6,7,8, Teng-Fu Hsieh9, Chia-Ling Hsieh1,2,3*

1 The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, 2 International Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, 3 TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan, 4 Office of Human Research, Taipei Medical University, Taipei, Taiwan, 5 International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 6 Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei, Taiwan, 7 Research Center of Biostatistics, College of Management, Taipei Medical University, Taipei, Taiwan, 8 Biostatistics Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, 9 Department of Urology, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan

* chsieh2@tmu.edu.tw

Abstract

Elevated Renal cell carcinoma (RCC) risk has been associated with the use of several antihypertensive medications but has not yet been elucidated in the populations prescribed alpha-1 blockers that are commonly used in the treatment of hypertension and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS-BPH). The aim of the present study was to investigate the association between alpha-1 blocker use and the risk of developing RCC using a nationwide population-based database in Taiwan. Patients who were treated with alpha-1 blockers for at least 28 days were identified through the Taiwan National Health Insurance Research Database from 2000 to 2010. The unexposed participants were matched with the exposed cases according to age, sex, and index year at a ratio of 3:1. Cox proportional hazards regression, stratified by sex and comorbidities and adjusted for age, was performed to estimate hazard ratios (HRs) for the risk of subsequent RCC. Among 2,232,092 subjects, patients who received alpha-1 blocker treatment had a higher risk of RCC than the unexposed group. Taking into account hypertension and BPH, the adjusted HR was significantly higher in male alpha-1 blocker users who had no BPH and either the presence (HR: 1.63, 95% confidence interval [CI] = 1.22–2.18) or absence (HR: 2.31, 95% CI = 1.40–3.81) of hypertension than in men not receiving these drugs. Taken together, male alpha-1 blocker users who had no comorbidity of BPH exhibited an increased risk for developing RCC independent of hypertension. Further study is warranted to elucidate the underlying mechanisms of this association.
Introduction

Renal cell carcinoma (RCC) is the most common malignant form of kidney cancer that arises from the renal epithelium. RCC accounts for 5% and 3% of all oncological diagnoses in men and in women, respectively [1] and is an often lethal malignancy for which there is no effective preventative and therapeutic strategy. Age and sex are strongly related to the risk of RCC. Overall, the incidence of RCC is approximately 1.6 to 2.0 times higher in men than in women after adjustment for age, and the estimated incidence increases in the older population, with a peak between 60 and 70 years of age [2]. Hypertension is also a risk factor for RCC; the relationship was identified in several large prospective cohort studies [3, 4]. In this regard, effective blood pressure control may lower the risk of RCC. However, several retrospective observational studies have found a link between elevated RCC risk and the use of antihypertensive medications, including diuretics, calcium channel blockers, beta-blockers, and angiotensin-converting enzyme inhibitors [5–8], although it is unclear whether the increased risk is caused by hypertension itself or by the use of antihypertensive medication.

Alpha-1 adrenoceptor antagonists (also called alpha-1 blockers) are a family of agents that cause a decrease in total peripheral resistance and are efficacious in the management of hypertension when used alone or in combination with other medications. Mechanistically, these drugs inhibit the effects of norepinephrine on the alpha-1 subtype of adrenergic receptors (α1-ARs) in blood vessels to promote vasodilation [9], and they also directly targets the smooth muscle cells in the prostate gland and bladder neck resulting in a decrease in smooth muscle tone and relief of bladder outflow obstruction [10]. Thus, alpha-1 blockers, although originally developed for the treatment of arterial hypertension, have become the first line of pharmacologic management for lower urinary tract symptoms in men with benign prostatic hyperplasia (LUTS-BPH) [11–13].

In addition to the traditional actions on smooth muscle relaxation and decrease in blood pressure, emerging studies have demonstrated the potentiation of alpha-1 blockers in growth inhibition, apoptosis, and angiogenesis suppression in an α1-adrenoceptor-independent manner. The potential mechanisms, including the inactivation of CDK [14], disruption of DNA integrity [15], engaging death receptor-mediated caspase-8 activation [16], induction of transforming growth factor-β signaling [17], downregulation of vascular endothelial growth factor [18, 19], and targeting focal adhesion survival signaling [20], have provided molecular underpinnings for the pharmacological exploitation of alpha-1 blocker therapy for a range of epithelial cancers, such as advanced prostate cancer, bladder cancer, and RCC [21].

Because of the increasing prevalence of BPH and hypertension with the increase in the mean age of the population, the use of alpha-1 blockers has steadily increased [22]. It is important to determine whether alpha-1 blockers could increase RCC incidence similarly to other reported antihypertensive drugs or conversely if they could decrease the risk through the proposed anticancer activity under current clinical practice. In this study, we aimed to investigate the relationship between alpha-1 blocker use and the risk of RCC using the National Health Insurance Research Database (NHIRD), a population-based database derived from the claims data of the National Health Insurance program of Taiwan [23].

Materials and methods

Data source

Data for this study were obtained from the NHIRD, which is derived from Taiwan’s National Health Insurance program and is currently maintained and regulated by the Data Science Center of the Taiwan Ministry of Health and Welfare for public research purposes. The NHIRD is
one of the largest administrative healthcare databases in the world, containing comprehensive clinical information of over 99% of Taiwan’s residents (approximately 23 million population) who were enrolled in this program. The datasets of NHIRD contain detailed healthcare information on demographics as well as all medical claims data, including patient demographics, medical visits, laboratory tests, procedures, prescriptions, and primary and secondary diagnoses based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding. The information in the NHIRD is stored in different datasheets; to protect patient privacy, data are de-identified secondary data [23].

Study population
We identified a cohort of patients with exposure to alpha-1 blocker medication in NHIRD on the basis of the presence of a prescription/dispensing record for at least 28 consecutive days in the study period from 1 January 2000 to 31 December 2010 (Accessed: July 2016). The 28th day after the date of the first prescription was set as the exposure index date. Eligible study subjects were those aged ≤90 years on the exposure index date who had not received the drug in the past 1 year (defined as new users). Patients who had a diagnostic record of malignancy, either RCC or any type of cancer, before or within 365 days after the exposure index date as identified using ICD-9-CM codes from the Registry for Catastrophic Illness Patients (RCIP) in the NHIRD were excluded from this study. The unexposed group consisted of patients who did not have a prescription record of alpha-1 blockers in the study period. The unexposed participants were matched with the exposed patients according to age, sex, and index year at a ratio of 3:1. Control patients were assigned the same index date as their matched cases. The unexposed cohort was subject to the same data quality checks and exclusions as the exposed cohort.

Exposure drugs
Data on all medications were collected using the Anatomical Therapeutic Chemical Classification system codes of the World Health Organization. The alpha-1 blockers investigated in this study included doxazosin (A043765100, A044681100, A044853100, A050263100, AC42378100, AC42874100, AC43467100, AC44621100 AC45013100; 2–8 mg/day), prazosin (AC26741100, AC267411G0, AC30415100, and AC39962100, B021220100, B021221100, B0212211G0; 1–8 mg/day), terazosin (A042936100, A043188100, A043317100, A043625100, A043656100, A043961100, AC44621100, AC4547100, B017664100; 2–10 mg/day), and tamsulosin (AB46016100, B024403100, B025413100; 0.2–0.8 mg/day).

Comorbidities and outcome
Comorbid medical disorders, including hypertension and BPH, before the exposure index date were investigated as the baseline comorbidities on the basis of all available history records in the NHIRD using the diagnosis codes ICD-9-CM 401–405 and ICD-9-CM 600, respectively. The outcome was a new diagnosis of RCC (ICD-9-CM: 189.0) given at a psychiatric contact (as in-patients or out-patients) and as identified in the RCIP after at least 365 days from the exposure index date.

Study follow-up
All cases of this study were followed up for the presence of incident RCC (ICD-9-CM: 189.0) over time until the occurrence of RCC or the end of the study period (December 31, 2010).
Statistical analysis

Standard descriptive methods were used to describe demographic and clinical characteristics and comorbid medical disorders for the total population, given as counts and corresponding percentages or as the mean and corresponding standard deviation. The incidence rate of RCC was measured using person-time of the total cohort follow-up and presented as a percentage or number per 100,000 person-years. Cox regression models were used to determine the associations between alpha-1 blocker use and RCC incidence by analyzing hazard ratios (HRs) and 95% confidence intervals (95% CIs). The multivariable analysis was adjusted for the predefined variables age, sex, Charlson comorbidity index (CCI) score, and comorbidities (hypertension and BPH) in the regression model. We also used Cox proportional hazards regression models to assess the interaction between alpha-1 blockers and comorbidities for incident RCC. The chi-square test was used to determine the relationship between different variables. Data management and analyses were performed using SAS 9.4 software (SAS Institute Inc., Cary, NC, USA). *P < .01* was considered statistically significant.

Ethics approval and consent to participate

This study was approved by the Taipei Medical University Research Ethics Committee (TMU-JIRB N201612053). Informed consent was waived because this was a retrospective study using NHIRD data.

Results

Characteristics of study participants

A flowchart of the study selection process is shown in Fig 1. In a sampling cohort of approximately 2.3 million participants enrolling between January 1, 2000 and December 31, 2010, a total of 582,941 patients were identified as new alpha-1 blocker users and classified as exposed after exclusion of those who were prescribed alpha-1 blockers in 2000, diagnosed as having RCC and other cancers prior to index day, and aged > 90 years. Another 1,649,151 patients, frequency-matched by age (every 5 years), sex, and index year of exposed subjects, were identified as the unexposed control group.

The baseline demographic data for the cohort are summarized in Table 1. Most participants in the alpha-1 blocker–exposed group were men (79.5%); the mean age was 65.26 ± 14.61 years. The unexposed control group was well matched for sex and age. Alpha-1 blockers are established medications for treating hypertension and LUTS-BPH [11–13]. As expected, a larger population of participants with comorbidities of hypertension and BPH was observed in the exposed group than in the control group (63.7% vs. 28.8% and 43.9% vs. 1.6%, respectively).

Among all 2,232,092 enrolled patients, 648 developed RCC during the study’s follow-up period. The unexposed and exposed groups had 359 and 289 patients with RCC, respectively. The prevalence rates of RCC were 3.90 per 100,000 person-years in the unexposed group and 8.91 per 100,000 person-years in the exposed group.

Association of the alpha-1 blockers exposed cohort with an increased risk of RCC

Table 2 shows the results of the multivariable analysis of the incidence of RCC. The patients in the alpha-1 blocker–exposed group had a significantly higher crude HR of 2.28 (95% CI, 1.96 –2.67; *P < .001*) than those in the unexposed control group. This association remained substantially unchanged (adjusted HR, 1.71; 95% CI, 1.402–2.091; *P < .001*) even after adjustment for potential confounders, including age, sex, CCI, and comorbidities of hypertension and...
BPH (adjusted model). Furthermore, hypertension was another risk factor for RCC (HR, 1.859; 95% CI, 1.553–2.226; P < .001), whereas age, sex, CCI score, and BPH were not the significant variables influencing RCC incidence.

Because hypertension and BPH were related to alpha-1 blocker use, we also performed a stratified analysis to determine whether these disease conditions influenced the effect of alpha-1 blockers on RCC. In this way (Table 3), an increased risk for RCC among alpha-1 blocker users was observed in the subgroup of patients without BPH (adjusted HR, 1.64; 95% CI, 1.33–2.22; P < .001) but not in those with BPH (adjusted HR, 0.95; 95% CI, 0.51–1.17; P < .001). Nonetheless, the adjusted HR of RCC was still higher in the alpha-1 blocker–exposed cohort, regardless of whether the patients were diagnosed as having hypertension (adjusted HR, 1.53; 95% CI, 1.21–1.93; P < .001 for the presence of hypertension; odds ratio, 1.06; 95% CI, 1.04–2.45; P < .05 for the absence of hypertension).

**Interaction of hypertension and BPH for association of alpha-1 blocker use and RCC risk**

When further stratified by sex (Table 4), a strong association between alpha-1 blocker use and RCC was found in men (HR, 1.89; 95% CI, 1.49–2.39) but not in women (HR, 1.44; 95% CI, 1.04–2.00).

**Table 1. Baseline characteristics of study participants after the matching procedure.**

| Variable          | α1- blocker Unexposed (N = 1,649,151) | Exposed (N = 582,941) |
|-------------------|---------------------------------------|-----------------------|
|                   | n          | %  | n          | %  |
| Gender            |            |    |            |    |
| Male              | 1,289,265  | 79.2| 463,702    | 79.5|
| Female            | 359,886    | 20.8| 119,239    | 20.5|
| Age, mean (SD)    |            |    |            |    |
| Hypertension      | 475,391    | 28.8| 371,087    | 63.7|
| BPH               | 25,820     | 1.6 | 255,735    | 43.9|
| Outcome           |            |    |            |    |
| RCC (per 100,000 person-years) | 359 | (3.90) | 289 | (8.91) |
In addition, among male participants, alpha-1 blocker users with hypertension conferred a significantly increased risk for RCC only when the patients did not have BPH (HR, 1.63; 95% CI, 1.22–2.18; P < .001). However, the association of alpha-1 blocker exposure and RCC risk seen in patients without BPH was still high in male populations, not only in the subgroup with hypertension but also in the one without hypertension (HR, 2.31; 95% CI, 1.40–3.81; P < .001). Notably, although women do not have a prostate and never develop BPH, no statistically significant interaction was found for hypertension with the association of alpha-1 blocker use and RCC incidence in women.

Taken together, a strong association was observed between alpha-1 blocker use and the risk of RCC in the male population, with the highest HR in those with neither hypertension nor BPH compared with the unexposed men.

Table 2. Crude and adjusted hazard ratios of RCC using Cox proportional hazard regression model.

| Characteristics       | Hazard ratios (95% confidence interval) | Crude | P-value | Adjusted model† | P-value |
|-----------------------|-----------------------------------------|-------|---------|-----------------|---------|
| Exposed group         | 2.28 (1.96–2.67)                        | <0.001* | 1.710 (1.402–2.091) | <0.001* |
| Age group (ref = 0–50 y) | 0.998 (0.992–1.004)                    | 0.529  | 0.990 (0.930–1.053) | 0.740   |
| Sex (ref = women)     | 1.048 (0.864–1.271)                     | 0.663  | 1.859 (1.533–2.226) | <0.001* |
| CCI score             | 1.00                                    |       | 1.168 (0.918–1.487) | 0.206   |

* P < 0.01
** P < 0.001 (Chi-square test)
† Adjusted model was adjusted for age, gender, CCI, and comorbidity of hypertension and BPH.

https://doi.org/10.1371/journal.pone.0242429.t002

Table 3. Subgroup analysis of the risk of RCC between exposed and unexposed groups according to sex and presence or absence of hypertension and BPH.

| Subgroup                              | No. of RCC | Adjusted HR (95% CI) † |
|---------------------------------------|------------|------------------------|
| alpha-1 blockers with BPH             |            |                        |
| Exposed                               | 116        | 0.95 (0.51–1.17)       |
| Unexposed                             | 11         | 1.00                   |
| alpha-1 blockers without BPH          |            |                        |
| Exposed                               | 173        | 1.64 (1.33–2.02) **    |
| Unexposed                             | 348        | 1.00                   |
| alpha-1 blockers with hypertension    |            |                        |
| Exposed                               | 204        | 1.53 (1.21–1.93) **    |
| Unexposed                             | 157        | 1.00                   |
| alpha-1 blockers without hypertension |            |                        |
| Exposed                               | 85         | 1.60 (1.04–2.45) *     |
| Unexposed                             | 202        | 1.00                   |

† Adjusted for age, gender, CCI, hypertension and BPH.
* P < 0.01
** P < 0.001 (Chi-square test).

https://doi.org/10.1371/journal.pone.0242429.t003
Discussion/conclusion

To our knowledge, this study is the first to determine the relationship between exposure to alpha-1 blockers and RCC incidence. This retrospective analysis provides the first epidemiologic evidence of the association of alpha-1 blocker use with an increased risk of RCC. Among men without a history of BPH, RCC was greatly associated with long-term use (>28 days) of alpha-1 blockers, whereas women showed no association after confounders were controlled for in the analysis. Although indications for alpha-1 blockers are LUTS-BPH and controlling blood pressure adequately for patients with hypertension, in Taiwan, physicians prescribed alpha-1 blockers also for other purposes, such as medical expulsive therapy for urolithiasis, treatment of neuropathic voiding dysfunction, improvement of bladder emptying from dysfunctional voiding and urinary retention, and reduction of total serum cholesterol level [24–26]. Thus, the recommendation of the present study to explore the risk of developing RCC after alpha-1 blocker use raises awareness among clinicians and public health authorities of the potential consequences of long-term use of alpha-1 blockers for indications other than LUTS-BPH.

A strength of our study is that it was a nationwide population-based study rather than involving a self-reported database. The NHIRD has nearly complete follow-up information regarding healthcare use by all study participants, and the dataset is routinely monitored. Considering the differences in age, sex, and comorbidities between the patients who did and did not receive alpha-1 blockers, propensity score matching was applied to select the control subjects. Nonetheless, we cannot exclude the limitations of the retrospective design, which completely relied on ICD-9-CM coding data for classifying BPH and hypertension. Even though the NH Bureau of Taiwan regularly performs audits on the validity of diagnosis, we did not evaluate the accuracy of RCC ICD-9-CM codes in the secondary position. In addition, established risk factors for RCC, such as obesity, tobacco use, family history of kidney cancer, and certain dietary factors, were not taken into consideration, owing to a lack of sufficient information conveyed in the codes. However, given the magnitude and statistical significance of the observed effects in this study, these limitations are unlikely to have compromised the results.

Only a few clinical studies have examined the relationship between alpha-1 blockers and cancer risk, and the results remain controversial. Researchers in a 5-year retrospective cohort

| Characteristics | No. of RCC (Exposed vs. Unexposed) | Adjusted HR (95% CI) † | α-1 blockers |
|-----------------|----------------------------------|------------------------|-------------|
|                 | Exposed                          | Unexposed              |             |
| Men             |                                  |                        |             |
| All             | 299 vs. 268                      | 1.89 (1.21–1.93)*      | 1 (Ref)     |
| Non-BPH + Non-hypertension | 18 vs. 148                  | 2.31 (1.40–3.81)*      | 1 (Ref)     |
| BPH + Non-hypertension    | 63 vs. 5                        | 1.05 (0.42–2.63)       | 1 (Ref)     |
| Non-BPH + hypertension  | 95 vs. 109                      | 1.63 (1.22–2.18)*      | 1 (Ref)     |
| BPH + hypertension      | 53 vs. 6                        | 0.85 (0.36–2.00)       | 1 (Ref)     |
| Women            |                                  |                        |             |
| All             | 60 vs. 91                        | 1.44 (0.99–2.11)       | 1 (Ref)     |
| Non-hypertension  | 4 vs. 49                        | 1.06 (0.37–3.06)       | 1 (Ref)     |
| hypertension    | 56 vs. 42                       | 1.48 (0.97–2.26)       | 1 (Ref)     |

* Chi-square test. Significance at \( p < 0.01 \)
† Adjusted for age and CCI.

https://doi.org/10.1371/journal.pone.0242429.t004
study at Lexington Veterans Affairs Medical Center observed that men exposed to quinazo-line-derived alpha-blockers (doxazosin, prazosin, and terazosin) were at a 1.46 times lower relative risk and 31.7% lower attributable risk for prostate cancer than untreated patients [27].

Another retrospective 20-year cohort study of men residing in Saskatchewan demonstrated that users of alpha-1 blockers, including alfuzosin, doxazosin, prazosin, tamsulosin, or terazosin, had an 11% lower risk of a prostate cancer diagnosis than nonusers [28]. However, in the Finnish Prostate Cancer Screening Trial, use of tamsulosin and alfuzosin had no effect on overall risk of prostate cancer [29]. Moreover, the positive association of prescribed alpha-1 blockers with prostate cancer risk was also observed in a nationwide cohort study in Denmark [30] and in a case–control analysis of a cohort study in Northern California [31]. Our present study investigating exposure to doxazosin, prazosin, terazosin and tamsulosin implies that alpha-1 blockers increase RCC incidence in men. The conflicting findings on the relationship between alpha-1 blockers and cancer risk remains unclear but may relate in part to the distinct chemical structures of drugs. In vitro studies demonstrated that quinazoline-based antagonists, including doxazosin, terazosin, and prazosin, induced apoptosis in benign and malignant prostate cells via an alpha-1-adrenoceptor-independent action [32–35]. However, the sulfonamide derivative tamsulosin does not elicit similar cytotoxic activity against cancer cells [36]. More robust trials with standardized stratification for comparing different classes of alpha-1 blockers are crucial to verifying the hazard assessment results.

Mechanistically, alpha-1 blockers selectively antagonize ARs through a postsynaptic blockade and thus inhibit smooth muscle contraction. Molecular biological studies have clearly defined three α1-AR subtypes: α1A (formerly named α1C), α1B, and α1D. These subtypes can be pharmacologically distinguished by their differential binding to alpha-1 blockers and may be linked to distinct second-messenger systems [37]. In the kidney, α1A- and α1D-ARs are the major functional subtypes other than α1B [38]. A previous in vitro study on rat cell lines transfected with human α1-AR cDNAs demonstrated that α1A- and α1D-ARs mediate G1-S cell cycle arrest, whereas the α1B-ARs mediate cell cycle progression [39]. The differential regulation of cell growth has been further evidenced in transgenic mice. Although long-term α1B-AR activation had no effect on cancer, α1A-AR stimulation prolonged lifespan in association with decreased cancer incidence [40]. Moreover, tamsulosin has a 10-fold greater affinity for α1A- and α1D-ARs than for α1B-ARs [41]. Accordingly, it can be suspected that long-term blockade of α1A- and α1D-ARs by using alpha-1 blockers, in particular the α1A/α1D-AR-selective antagonist tamsulosin, may increase cancer risk, which may account in part for our present findings of a strong association of alpha-1 blocker use with RCC incidence. However, this explanation cannot clarify why the risk association exists only in men and not in women. Further elucidation of sex differences in relation to the α1-AR subtype distribution and functional response to alpha-1 blockers could lead to a better understanding of the underlying mechanisms.

**Acknowledgments**

We thank Wallace Academic Editing for reviewing and editing the English writing.

**Author Contributions**

**Conceptualization:** Shian-Ying Sung, Chia-Ling Hsieh.

**Data curation:** Jin-Hua Chen.

**Formal analysis:** Trang Thi Huynh Le, Jin-Hua Chen.

**Funding acquisition:** Shian-Ying Sung.
Investigation: Shian-Ying Sung.

Methodology: Jin-Hua Chen.

Supervision: Chia-Ling Hsieh.

Writing – original draft: Trang Thi Huynh Le, Teng-Fu Hsieh.

Writing – review & editing: Chia-Ling Hsieh.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7–30. https://doi.org/10.3322/caac.21590 PMID: 31912902

2. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019; 75(1):74–84. https://doi.org/10.1016/j.eururo.2018.08.036 PMID: 30243799

3. Colt JS, Schwartz K, Graubard BI, Davis F, Rut erbush J, DiGaetano R, et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology. 2011; 22(6):797–804. https://doi.org/10.1097/EDC.0b013e3182300720 PMID: 21881515

4. Weikert S, Boeing H, Pis chin T, Weikert C, Olsen A, Tjonneland A, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008; 167(4):438–46. https://doi.org/10.1093/aje/kwm321 PMID: 18048375

5. Colt JS, Hofmann JN, Schwartz K, Chow WH, Graubard BI, Davis F, et al. Antihypertensive medication use and risk of renal cell carcinoma. Cancer Causes Control. 2017; 28(4):89–97. https://doi.org/10.1007/s10552-017-0857-3 PMID: 28224412

6. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sorensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 2005; 92(7):1302–6. https://doi.org/10.1038/sj.bjc.6602490 PMID: 15812478

7. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol. 1999; 83(7):1090–3. https://doi.org/10.1016/s0002-9149(99)00021-1 PMID: 10190526

8. Xie Y, Xu P, Wang M, Zheng Y, Tian T, Yang S, et al. Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis. Aging (Albany NY). 2020; 12(2):1545–62. https://doi.org/10.18632/aging.102699 PMID: 31986309

9. Nash DT. Alpha-adrnergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clin Cardiol. 1990; 13(11):764–72. https://doi.org/10.1097/00033088-199011000-00008 PMID: 24760836

10. Andersson KE, Gratze C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007; 24(1):21–8. https://doi.org/10.1097/MOU.0b00000000000007 PMID: 17615548

11. Silva J, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Curr Opin Urol. 2014; 24(1):21–8. https://doi.org/10.1097/MOU.0000000000000007 PMID: 24231531

12. Oelke M, Bachmann A, Desczaeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013; 64(1):118–40. https://doi.org/10.1016/j.eururo.2013.03.004 PMID: 23541338

13. McVary KT, Rohrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185(5):1793–803. https://doi.org/10.1016/j.juro.2011.01.074 PMID: 21420124

14. Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH, et al. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts. Prostate. 2009; 69(6):610–23. https://doi.org/10.1002/pros.20919 PMID: 19143029

15. Youn YH, Yang H, Yoon YD, Kim DY, Lee C, Yoo TK. Doxazosin-induced clusterin expression and apoptosis in prostate cancer cells. Urol Oncol. 2007; 25(6):483–8. https://doi.org/10.1016/j.uroonc.2007.02.010 PMID: 18047956

16. Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res. 2006; 66(1):464–72. https://doi.org/10.1158/0008-5472.CAN-05-2039 PMID: 16397262
17. Partin JV, Anglin IE, Kyprianou N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer. 2003; 88(10):1615–21. https://doi.org/10.1038/sj.bjc.6600961 PMID: 12771931

18. Garrison JB, Shaw YJ, Chen CS, Kyprianou N. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res. 2007; 67(23):11344–52. https://doi.org/10.1158/0008-5472.CAN-07-1662 PMID: 18056461

19. Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem. 2005; 94(2):374–88.

20. Sakamoto S, Schwarze S, Kyprianou N. Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur Urol. 2011; 59(5):734–44.

21. Gotoh A, Nagaya H, Kanno T, Nishizaki T. Anti-tumor action of alpha(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells. Pharmacology. 2012; 90(5–6):242–6. https://doi.org/10.1159/000342797 PMID: 23007551

22. Cindolo L, Pirozzi L, Fanizza C, Romero M, Sountoulides P, Roehrborn CG, et al. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men. Int Urol Nephrol. 2013.

23. National Health Insurance Research Database, Taiwan 2014 [Available from: https://nhird.nhri.org.tw/en/.

24. Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol. 2005; 173(6):2010–2. PMID: 15879806

25. Austin PF, HormyYL, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol. 2005; 173(6):2010–2. PMID: 15879806

26. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol. 2007; 178(5):2176–80. https://doi.org/10.1016/j.juro.2007.06.043 PMID: 17870114

27. Van Rompay MI, Curtis Nickel J, Ranganathan G, Kantoff PW, Solomon KR, Lund JL, et al. Impact of 5alpha-reductase inhibitor and alpha-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. BJU Int. 2019; 123(3):511–8. https://doi.org/10.1111/bju.14534 PMID: 30216624

28. Friedmann GD, Udaltsova N, Habel LA. Norepinephrine antagonists and cancer risk. Int J Cancer. 2011; 128(3):737–8; author reply 9. https://doi.org/10.1002/ijc.25351 PMID: 20333678

29. Murtola TJ, Tammela TL, Maatmanen L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer. 2009; 101(5):843–6. https://doi.org/10.1038/sj.bjc.6605188 PMID: 19654575

30. Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol. 2011; 60(4):691–8. https://doi.org/10.1016/j.eururo.2011.06.016 PMID: 21705134

31. Friedman GD, Udaltsova N, Habal LA. Norepinephrine antagonists and cancer risk. Int J Cancer. 2011; 128(3):737–8; author reply 9. https://doi.org/10.1002/ijc.25351 PMID: 20333678

32. Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res. 2002; 62(2):597–602. PMID: 11809715

33. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol. 1999; 161(6):2002–8. PMID: 10332490

34. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000; 60(16):4550–5. PMID: 10969806

35. Lin SC, Chueh SC, Hsiao CJ, Li TK, Chen TH, Liao CH, et al. Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia. 2007; 9(10):830–9. https://doi.org/10.1593/neo.07475 PMID: 17971903

36. Yamada D, Nishimatsu H, Kumano S, Hirano Y, Suzuki M, Fujimura T, et al. Reduction of prostate cancer incidence by naftopidil, an alpha1-adrenoceptor antagonist and transforming growth factor-beta signaling inhibitor. Int J Urol. 2013; 20(12):1220–7. https://doi.org/10.1111/iju.12156 PMID: 23600973
37. Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res. 2001; 44(3):195–208. https://doi.org/10.1006/phrs.2001.0857 PMID: 11529686

38. Karabacak OR, Sener NC, Yilmazer D, Karabacak Y, Goktug HN, Yigilbasi O, et al. Alpha adrenergic receptors in renal pelvis and calyces: can rat models be used? Int Braz J Urol. 2014; 40(5):683–9. https://doi.org/10.1590/S1677-5538.IBJU.2014.05.14 PMID: 25498280

39. Gonzalez-Cabrera PJ, Shi T, Yun J, McCune DF, Rorabaugh BR, Perez DM. Differential regulation of the cell cycle by alpha1-adrenergic receptor subtypes. Endocrinology. 2004; 145(11):5157–67. https://doi.org/10.1210/en.2004-0728 PMID: 15297446

40. Collette KM, Zhou XD, Amoth HM, Lyons MJ, Papay RS, Sens DA, et al. Long-term alpha1B-adrenergic receptor activation shortens lifespan, while alpha1A-adrenergic receptor stimulation prolongs lifespan in association with decreased cancer incidence. Age (Dordr). 2014; 36(4):9675. https://doi.org/10.1007/s11357-014-9675-7 PMID: 24994537

41. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008; 15(3):193–9. https://doi.org/10.1111/j.1442-2042.2007.01956.x PMID: 18304211